Evidence map›Paper›PMID 25461761›Full record

ArticlePloS one2014

Prognostic significance of interleukin-8 and CD163-positive cell-infiltration in tumor tissues in patients with oral squamous cell carcinoma.

Yohei Fujita, Masato Okamoto, Hiroyuki Goda, Tomoyuki Tano, Koh-ichi Nakashiro, Atsuro Sugita, Tomonobu Fujita, Shigeo Koido, Sadamu Homma, Yutaka Kawakami and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 2 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Prognostic Role of CD68British journal of biomedical science · 2023
    Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Immune Cells in Head-and-Neck Tumor Microenvironments.Journal of personalized medicine · 2022
    Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Yohei FujitaDepartment of Oral and Maxillofacial Surgery, Ehime University Graduate School of Medicine, Ehime, Japan.
Masato OkamotoDepartment of Advanced Immunotherapeutics, Kitasato University School of Pharmacy, Tokyo, Japan; Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan.
Hiroyuki GodaDepartment of Oral and Maxillofacial Surgery, Ehime University Graduate School of Medicine, Ehime, Japan.
Tomoyuki TanoDepartment of Oral and Maxillofacial Surgery, Ehime University Graduate School of Medicine, Ehime, Japan.
Koh-ichi NakashiroDepartment of Oral and Maxillofacial Surgery, Ehime University Graduate School of Medicine, Ehime, Japan.
Atsuro SugitaDepartment of Pathology, Ehime University Hospital, Ehime, Japan.
Tomonobu FujitaDivision of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan.
Shigeo KoidoDivision of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Sadamu HommaDepartment of Oncology, Institute of DNA Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Yutaka KawakamiDivision of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan.
Hiroyuki HamakawaDepartment of Oral and Maxillofacial Surgery, Ehime University Graduate School of Medicine, Ehime, Japan.
Ehime University · JPJikei University School of Medicine · JPKeio University · JPEhime University Hospital · JPKitasato University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe investigated whether serum interleukin (IL)-8 reflects the tumor microenvironment and has prognostic value in patients with oral squamous cell carcinoma (OSCC). EXPERIMENTAL

designFifty OSCC patients who received radical resection of their tumor(s) were enrolled. Preoperative sera were measured for IL-8 by ELISA. Expression of IL-8 and the infiltration of immune cells in tumor tissues were analyzed by an immunohistochemical staining of surgical specimens.

resultsWe found that disease-free survival (DFS) was significantly longer in the Stage I/II OSCC patients with low serum IL-8 levels compared to those with high levels (p = 0.001). The tumor expression of IL-8, i.e., IL-8(T) and the density of CD163-positive cells in the tumor invasive front, i.e., CD163(IF) were correlated with the serum IL-8 level (p = 0.033 and p = 0.038, respectively), and they were associated with poor clinical outcome (p = 0.007 and p = 0.002, respectively, in DFS) in all patients. A multivariate analysis revealed that N status, IL-8(T) and CD163(IF) significantly affected the DFS of the patients. Further analysis suggested that combination of N status with serum IL-8, IL-8(T) or CD163(IF) may be a new criterion for discriminating between OSCC patients at high and low risk for tumor relapse. Interestingly, the in vitro experiments demonstrated that IL-8 enhanced generation of CD163-positive M2 macrophages from peripheral blood monocytes, and that the cells produced IL-10.

conclusionsThese findings indicate that IL-8 may be involved in poor clinical outcomes via generation of CD163-positive M2 macrophages, and that these factors in addition to N status may have prognostic value in patients with resectable OSCSS.

Indexed as

Gene Expression Regulation, NeoplasticAgedAged, 80 and overAntigens, CDAntigens, Differentiation, MyelomonocyticCarcinoma, Squamous CellCD163 AntigenDisease-Free SurvivalEnzyme-Linked Immunosorbent AssayFemaleFlow CytometryHumansImmunohistochemistryInterleukin-10Interleukin-8MaleAntigens, CDAntigens, Differentiation, MyelomonocyticCD163 AntigenCXCL8 protein, humanInterleukin-10Interleukin-8Receptors, Cell Surface

Identifiers

PMID25461761
PMCPMC4251830
OpenAlexW2019237340

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.